MCID: SRC014
MIFTS: 66

Sarcoma malady

Categories: Cancer diseases, Bone diseases

Aliases & Classifications for Sarcoma

About this section

Aliases & Descriptions for Sarcoma:

Name: Sarcoma 11 27 50 13 68
Connective and Soft Tissue Neoplasm 11
 
Tumor of Soft Tissue and Skeleton 11
Sarcoma - Category 68

Classifications:



External Ids:

Disease Ontology11 DOID:1115
ICD1030 C49
SNOMED-CT62 187985009, 93765001
ICD9CM32 171, 171.9

Summaries for Sarcoma

About this section
Disease Ontology:11 A cell type cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary: Sarcoma, also known as connective and soft tissue neoplasm, is related to mediastinum sarcoma and kaposi sarcoma. An important gene associated with Sarcoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways are p38MAPK events and JNK signaling in the CD4+ TCR pathway. The drugs thiotepa and ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and kidney, and related mouse phenotypes are Decreased viability in HMC1.1 cells and Increased cell viability after pRB stimulation.

Wikipedia:71 A sarcoma (plural sarcomas or sarcomata; from the Greek σάρξ sarx meaning \"flesh\") is a... more...

Related Diseases for Sarcoma

About this section

Diseases related to Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 793)
idRelated DiseaseScoreTop Affiliating Genes
1mediastinum sarcoma32.8ASPSCR1, EWSR1, KIT
2kaposi sarcoma12.5
3ewing sarcoma12.3
4follicular dendritic cell sarcoma12.2
5alveolar soft-part sarcoma12.2
6myeloid sarcoma12.2
7endometrial stromal sarcoma12.2
8soft tissue sarcoma12.2
9epithelioid sarcoma12.1
10langerhans cell sarcoma12.1
11clear cell sarcoma12.1
12mast-cell sarcoma12.1
13interdigitating dendritic cell sarcoma12.1
14sarcoma, synovial12.1
15histiocytic sarcoma12.1
16spindle cell sarcoma12.1
17paraganglioma and gastric stromal sarcoma12.0
18uterine sarcoma12.0
19undifferentiated pleomorphic sarcoma12.0
20prostate stromal sarcoma12.0
21retroperitoneal sarcoma12.0
22bladder sarcoma12.0
23heart sarcoma12.0
24kidney clear cell sarcoma12.0
25liver sarcoma12.0
26esophagus sarcoma11.9
27gallbladder sarcoma11.9
28reticulum cell sarcoma11.9
29bone ewing's sarcoma11.9
30small intestinal sarcoma11.8
31vulvar alveolar soft part sarcoma11.8
32mediastinum synovial sarcoma11.8
33extraosseous ewing's sarcoma11.8
34trachea sarcoma11.8
35paranasal sinus sarcoma11.8
36rectum sarcoma11.8
37rectum kaposi's sarcoma11.8
38colon kaposi sarcoma11.8
39biphasic synovial sarcoma11.8
40meninges sarcoma11.8
41kidney sarcoma11.8
42monophasic synovial sarcoma11.8
43penis sarcoma11.8
44testis sarcoma11.8
45bile duct sarcoma11.8
46anus sarcoma11.8
47cervical alveolar soft part sarcoma11.8
48kidney osteogenic sarcoma11.8
49breast sarcoma11.8
50spindle cell synovial sarcoma11.8

Graphical network of the top 20 diseases related to Sarcoma:



Diseases related to sarcoma

Symptoms & Phenotypes for Sarcoma

About this section

GenomeRNAi Phenotypes related to Sarcoma according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00105-A-011.0KIT, LYN, SRC
2GR00230-A-110.8FES, KIT, MOS, YES1
3GR00055-A-110.6BRAF, CRK, FES, HRAS, LYN, YES1
4GR00366-A-19210.6BRAF, SSX1, SSX2, SSX3, SSX5
5GR00193-A-310.5FES, KIT, MOS, YES1, BRAF, KIT

MGI Mouse Phenotypes related to Sarcoma according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000200610.4BRAF, FES, FLI1, HRAS, KIT, MOS
2MP:001077110.3BRAF, FES, HRAS, JUN, KIT, LYN
3MP:00036319.7BRAF, CRK, FES, FLI1, HRAS, JUN
4MP:00053889.5BRAF, CRK, HRAS, JUN, KIT, LYN

Drugs & Therapeutics for Sarcoma

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)16 Company Approval Date
1
Doxil16 44 DOXORUBICIN HYDROCHLORIDE Alza June 1999
FDA Label: Doxil
Disease/s that Drug Treats:ovarian cancer that is refractory to other first-line therapies
Indications and Usage:16 DOXIL is an anthracycline topoisomerase II inhibitor indicated for: Ovarian cancer (1.1)After failure of platinum-based chemotherapy. AIDS-related Kaposi’s Sarcoma (1.2)After failure of prior systemic chemotherapy or intolerance to such therapy. Multiple Myeloma (1.3)In combination with bortezomib in patients who have not previouslyreceived bortezomib and have received at least one prior therapy.
DrugBank Targets:14 1. DNA;2. DNA topoisomerase 2-alpha
Mechanism of Action:16 
Target: nucleic acidsynthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action ofdoxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acidsynthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclearReference ID: 373359617 chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, andinduction of mutagenesis and chromosomal aberrations.
2
Fusilev16 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
FDA Label: Fusilev
Disease/s that Drug Treats:rescue after high-dose methotrexate therapy in osteosarcoma and to reduce the toxicity of methotrexate
Indications and Usage:16 Fusilev is a folate analog indicated for: Rescue after high-dose methotrexate therapy in osteosarcoma. Diminishing the toxicity and counteracting the effects of impairedmethotrexate elimination and of inadvertent overdosage of folic acidantagonists. Use in combination chemotherapy with 5-fluorouracil in the palliativetreatment of patients with advanced metastatic colorectal cancer.(1)Limitations of UseFusilev is not approved for pernicious anemia and megaloblastic anemias.Improper use may cause a hematologic remission while neurologicmanifestations continue to progress. (1.1)
DrugBank Targets:14 1. Thymidylate synthase
Mechanism of Action:16 
Target: therapeutic and toxic effects of folic acidantagonists / therapeutic and toxic effects of fluoropyrimidines used in cancer therapy
Action: counteract/enhance
FDA: 12.1.1 Levoleucovorin effects during high-dose methotrexate therapyLevoleucovorin is the pharmacologically active isomer of 5-formyl tetrahydrofolic acid. Levoleucovorin does not requirereduction by the enzyme dihydrofolate reductase in order to participate in reactions utilizing folates as a source of “onecarbon”moieties. Administration of levoleucovorin can counteract the therapeutic and toxic effects of folic acidantagonists such as methotrexate, which act by inhibiting dihydrofolate reductase.12.1.2 Levoleucovorin effects in combination with 5-fluorouracilLevoleucovorin can enhance the therapeutic and toxic effects of fluoropyrimidines used in cancer therapy such as5-fluorouracil. 5-fluorouracil is metabolized to 5-fluoro-2'-deoxyuridine-5'-monophosphate (FdUMP), which binds to andinhibits thymidylate synthase (an enzyme important in DNA repair and replication). Levoleucovorin is readily convertedto another reduced folate, 5,10-methylenetetrahydrofolate, which acts to stabilize the binding of FdUMP to thymidylatesynthase and thereby enhances the inhibition of this enzyme.
3
Intron A16 44 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
FDA Label: Intron A
Disease/s that Drug Treats:non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:16 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years ofage or older with hairy cell leukemia.Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment inpatients 18 years of age or older with malignant melanoma who are free of disease butat high risk for systemic recurrence, within 56 days of surgery.Follicular Lymphoma INTRON A is indicated for the initial treatment of clinicallyaggressive (see Clinical Pharmacology) follicular Non-Hodgkin’s Lymphoma inconjunction with anthracycline-containing combination chemotherapy in patients 18years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumorburden follicular Non-Hodgkin’s Lymphoma has not been demonstrated.Condylomata Acuminata INTRON A is indicated for intralesional treatment of selectedpatients 18 years of age or older with condylomata acuminata involving externalsurfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).The use of this product in adolescents has not been studied.AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selectedpatients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihoodof response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immunesystem as indicated by total CD4 count.Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C inpatients 18 years of age or older with compensated liver disease who have a history ofblood or blood-product exposure and/or are HCV antibody positive. Studies in thesepatients demonstrated that INTRON A therapy can produce clinically meaningful effectson this disease, manifested by normalization of serum alanine aminotransferase (ALT)and reduction in liver necrosis and degeneration.A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.Patients should be tested for the presence of antibody to HCV. Patients with othercauses of chronic hepatitis, including autoimmune hepatitis, should be excluded. Priorto initiation of INTRON A therapy, the physician should establish that the patient hascompensated liver disease. The following patient entrance criteria for compensated liverdisease were used in the clinical studies and should be considered before INTRON Atreatment of patients with chronic hepatitis C: No history of hepatic encephalopathy, variceal bleeding, ascites, or otherclinical signs of decompensation Bilirubin Less than or equal to 2 mg/dL Albumin Stable and within normal limits Prothrombin Time Less than 3 seconds prolonged WBC Greater than or equal to 3000/mm3 Platelets Greater than or equal to 70,000/mm3Serum creatinine should be normal or near normal.Prior to initiation of INTRON A therapy, CBC and platelet counts should beevaluated in order to establish baselines for monitoring potential toxicity. These testsshould be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, andmonthly thereafter. Serum ALT should be evaluated at approximately 3-month intervalsto assess response to treatment (see DOSAGE AND ADMINISTRATION).Patients with preexisting thyroid abnormalities may be treated if thyroidstimulatinghormone (TSH) levels can be maintained in the normal range by medication.TSH levels must be within normal limits upon initiation of INTRON A treatment and TSHtesting should be repeated at 3 and 6 months (see PRECAUTIONS, LaboratoryTests).INTRON A in combination with REBETOL® is indicated for the treatment ofchronic hepatitis C in patients 3 years of age and older with compensated liver diseasepreviously untreated with alpha interferon therapy and in patients 18 years of age andolder who have relapsed following alpha interferon therapy. See REBETOL prescribinginformation for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B inpatients 1 year of age or older with compensated liver disease. Patients who have beenserum HBsAg positive for at least 6 months and have evidence of HBV replication(serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studiesin these patients demonstrated that INTRON A therapy can produce virologic remissionof this disease (loss of serum HBeAg) and normalization of serum aminotransferases.INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy beperformed to establish the presence of chronic hepatitis and the extent of liver damage.The physician should establish that the patient has compensated liver disease. Thefollowing patient entrance criteria for compensated liver disease were used in theclinical studies and should be considered before INTRON A treatment of patients withchronic hepatitis B: No history of hepatic encephalopathy, variceal bleeding, ascites, or othersigns of clinical decompensation Bilirubin Normal Albumin Stable and within normal limits Prothrombin Time Adults less than 3 seconds prolongedPediatrics less than or equal to 2 seconds prolonged WBC Greater than or equal to 4000/mm3 Platelets Adults greater than or equal to 100,000/mm3Pediatrics greater than or equal to 150,000/mm3Patients with causes of chronic hepatitis other than chronic hepatitis B or chronichepatitis C should not be treated with INTRON A. CBC and platelet counts should beevaluated prior to initiation of INTRON A therapy in order to establish baselines formonitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, andALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,since patients may become virologic responders during the 6-month periodfollowing the end of treatment. In clinical studies in adults, 39% (15/38) of respondingpatients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Ofresponding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.A transient increase in ALT greater than or equal to 2 times baseline value (flare)can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adultsand pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy andwas more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than innonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults andpediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equalto 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) duringtherapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinicalsymptomatology and liver function tests including ALT, prothrombin time, alkalinephosphatase, albumin, and bilirubin, should be monitored at approximately 2-weekintervals (see WARNINGS).
DrugBank Targets:14 1. Interferon alpha/beta receptor 2;2. Interferon alpha/beta receptor 1
Mechanism of Action:16 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
4
Taxol16 44 PACLITAXEL Bristol-Myers Squibb August 1997
FDA Label: Taxol
Disease/s that Drug Treats:Kaposi's Sarcoma
Indications and Usage:16 Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma ofthe ovary. As first-line therapy, Paclitaxel Injection, USP is indicated in combination with cisplatin.Paclitaxel Injection, USP is indicated for the adjuvant treatment of node-positive breast canceradministered sequentially to standard doxorubicin-containing combination chemotherapy.. In the clinicaltrial, there was an overall favorable effect on disease-free and overall survival in the total population ofpatients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen andprogesterone receptor-negative tumors (see CLINICAL STUDIES, Breast Carcinoma).Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combinationchemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapyshould have included an anthracycline unless clinically contraindicated.Paclitaxel Injection, USP, in combination with cisplatin, is indicated for the first-line treatment of nonsmallcell lung cancer in patients who are not candidates for potentially curative surgery and/or radiationtherapy.Paclitaxel Injection, USP is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma.
DrugBank Targets:14 1. Apoptosis regulator Bcl-2;2. Tubulin beta-1 chain;3. Nuclear receptor subfamily 1 group I member 2;4. Microtubule-associated protein 4;5. Microtubule-associated protein 2;6. Microtubule-associated protein tau
Mechanism of Action:16 
Target: microtubules
Action: promoter of assembly & preventor of depolymerization
FDA: Paclitaxel is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulindimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibitionof the normal dynamic reorganization of the microtubule network that is essential for vital interphase andmitotic cellular functions. In addition, paclitaxel induces abnormal arrays or “bundles” of microtubulesthroughout the cell cycle and multiple asters of microtubules during mitosis.Following intravenous administration of paclitaxel, paclitaxel plasma concentrations declined in abiphasic manner. The initial rapid decline represents distribution to the peripheral compartment andelimination of the drug. The later phase is due, in part, to a relatively slow efflux of paclitaxel from theperipheral compartment.Pharmacokinetic parameters of paclitaxel following 3- and 24-hour infusions of paclitaxel at dose levelsof 135 and 175 mg/m2 were determined in a Phase 3 randomized study in ovarian cancer patients and aresummarized in the following table:
5
Votrient16 44 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009
FDA Label: Votrient
Disease/s that Drug Treats:soft tissue sarcoma/ renal cell carcinoma
Indications and Usage:16 VOTRIENT is a kinase inhibitor indicated for the treatment of patients with: advanced renal cell carcinoma. (1) advanced soft tissue sarcoma who have received prior chemotherapy. (1)Limitation of Use: The efficacy of VOTRIENT for the treatment of patientswith adipocytic soft tissue sarcoma or gastrointestinal stromal tu mors has notbeen demonstrated.
DrugBank Targets:14 1. Vascular endothelial growth factor receptor 1;2. Vascular endothelial growth factor receptor 2;3. Vascular endothelial growth factor receptor 3;4. Platelet-derived growth factor receptor alpha;5. Platelet-derived growth factor receptor beta;6. Mast/stem cell growth factor receptor Kit;7. Fibroblast growth factor receptor 3;8. Tyrosine-protein kinase ITK/TSK;9. Fibroblast growth factor 1;10. SH2B adapter protein 3
Mechanism of Action:16 
Target: vascular epidermal growth factor receptor (VEGFR) tyrosine kinase
Action: inhibitor
FDA: Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factorreceptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-αand -β, fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), andtransmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibitedligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-β receptors. In vivo,pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis ina mouse model, and the growth of some human tumor xenografts in mice.

Drugs for Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 596)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
BleomycinapprovedPhase 4, Phase 3, Phase 2, Phase 115911056-06-75360373
Synonyms:
(betaR)-N(alpha)-{[6-amino-2-((1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl)-5-methylpyrimidin-4-yl]carbonyl}-beta-{2-O-[3-O-(aminocarbonyl)-alpha-D-mannopyranosyl]-alpha-L-gulopyranosyloxy}-N-[(1R,2S,3S)-5-({(1S,2R)-1-[({2-[4-({[3-(dimethylsulfonio)propyl]amino}carbonyl)-2,4'-bi-1,3-thiazol-2'-yl]ethyl}amino)carbonyl]-2-hydroxypropyl}amino)-3-hydroxy-4-methyl-5-oxopentan-2-yl]-L-histidinamide
11056-06-7
11116-31-7
1400-95-9
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[3-[4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
37208-04-1
37293-16-6
37353-43-8
9041-93-4
9041-93-4 (sulfate (salt))
AC1L9UFF
AC1NSEJD
AC1NUTOQ
BLM
Blenoxane
Bleo
Bleocin
Bleogin
Bleomicin
Bleomicina
Bleomicina [INN-Spanish]
Bleomycin A(2)
Bleomycin A2
Bleomycin A2 & Bleomycin B2.
Bleomycin B(2)
Bleomycin B2
Bleomycin sulfate
Bleomycin sulphate
 
Bleomycine
Bleomycine [INN-French]
Bleomycins
Bleomycinum
Bleomycinum [INN-Latin]
C06854
C55H85N17O21S3
C55H86N17O21S3
CCRIS 2754
CHEBI:3139
CHEMBL403664
CID456190
CID5360373
CID5460769
DB00290
EINECS 234-356-5
HSDB 3208
LMPK14000006
LS-44860
LS-524
N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide
N1-(3-(Dimethylsulfonio)propyl)bleomycinamide
NDC 0015-3010
NSC 125066
Pingyangmyvin A2
STOCK1N-74760
UNII-13M89UEA7W
UNII-40S1VHN69B
Zhengguangmycin A2
Zhengguangmycin A2 [Chinese]
bleomycin
bleomycin a2
2
Doxorubicinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1175123214-92-831703
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-Hydroxydaunomycin
14-Hydroxydaunorubicine
14-hydroxydaunomycin
14-hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
ADM
ADR
Adriablastin
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin Semiquinone
Adriamycin semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (TN)
Adriblastina (hydrochloride salt)
Aerosolized Doxorubicin
BPBio1_000502
BRD-K92093830-003-04-3
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
CCRIS 739
CHEBI:28748
CHEMBL179
CID31703
Caelyx
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
DOX-SL
Doxil
Doxo
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin HCl
 
Doxorubicin Hydrochloride
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicine
Doxorubicine [INN-French]
Doxorubicinum
Doxorubicinum [INN-Latin]
EINECS 245-495-6
FI 106
Farmablastina (hydrochloride salt)
HMS2089H06
HSDB 3070
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
LMPK13050001
LS-1029
LS-165655
MLS000759533
Myocet
NCI-C01514
NChemBio.2007.10-comp13
NDC 38242-874
NIOSH/JT9100000
NSC 123127
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
TLC D-99
ThermoDox
Triferric doxorubicin
UNII-80168379AG
adiblastine (hydrochloride salt)
adr iablatina (hydrochloride salt)
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
adriblatina (hydrochloride salt)
doxorubicin
nchembio809-comp5
3
Efavirenzapproved, investigationalPhase 4, Phase 3409154598-52-464139
Synonyms:
(-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(-)-Efavirenz
(4S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(4S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one
(4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-(2-cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-ben
(S)-6-Chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-Chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[d][1,3]oxazin-2-one
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one
154598-52-4
1ikv
1ikw
2H-3,1-Benzoxazin-2-one, 6-chloro-4-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-, (4S)- (9
6-chloro-4-(2-Cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one
6-chloro-4-(2-cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
AC-19049
AC1L20IX
BIDD:GT0383
C08088
C14H9ClF3NO2
CHEBI:119486
CHEMBL223228
CID64139
CPD000466351
D00896
DB00625
DB07709
DMP 266
DMP-266
EFV
 
EFZ
Efavirenz
Efavirenz (JAN/INN)
Efavirenzum
Eravirenz
HMS2051J08
HMS2090N16
HSDB 7163
L 743726
L-741211
L-743,726
L-743725
L-743726
LS-173464
MLS000759465
MLS001424087
Met-SDF-1.beta. & Efavirenz
Met-Stromal Cell-derived Factor-1.beta. (Human) & Efavirenz
MolPort-003-983-924
NSC742403
SAM001246667
SBB066062
SMR000466351
Stocrin
Strocin (TM)
Sustiva
Sustiva (TM)
Sustiva (TN)
UNII-JE6H2O27P8
ZINC02020233
efavirenz
efavirenz, (S)-isomer
zoxazin-2-one
Éfavirenz
4
Vincristineapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 19222068-78-2, 57-22-75978
Synonyms:
22-Oxovincaleukoblastin
22-Oxovincaleukoblastine
28379-27-3
57-22-7
AC1L1LJC
C07204
C46H56N4O10
CCRIS 5763
CHEBI:28445
CID5978
D08679
DB00541
EINECS 200-318-1
HMS2090E19
HSDB 3199
Indole alkaloid
LCR
LS-228
Leurocristine
Lilly 37231 (1:1 sulfate salt)
Liposomal Vincristine
Marqibo
NCGC00163700-01
NCI-C04864
NCI60_026703
NSC-67574
Onco TCS
 
Oncovin
Oncovin (1:1 sulfate salt)
Oncovine
Tecnocris
Tecnocris (TN)
UNII-5J49Q6B70F
VCR
VIN
Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine
Vincasar
Vincasar (1:1 sulfate salt)
Vincasar PFS
Vincrex
Vincrex (1:1 sulfate salt)
Vincristin
Vincristina
Vincristina [DCIT]
Vincristine (INN)
Vincristine Sulfate
Vincristine Sulfate PFS
Vincristine [INN:BAN]
Vincristinum
Vincristinum [INN-Latin]
Vincrstine
Vincrystine
Vinkristin
Z-D-Val-Lys(Z)-OH
vincristine
5
Cyclophosphamideapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 1293550-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Anhydrous cyclophosphamide
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
 
DB00531
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
6
Ritonavirapproved, investigationalPhase 4, Phase 2, Phase 3, Phase 1883155213-67-5392622
Synonyms:
1,3-thiazol-5-ylmethyl N-[(2S,3S,5S)-3-hydroxy-5-[[(2S)-3-methyl-2-[[methyl-[(2-propan-2-yl-1,3-thiazol-4-yl)methyl]carbamoyl]amino]butanoyl]amino]-1,6-diphenylhexan-2-yl]carbamate
155213-67-5
1hxw
1sh9
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S)-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
5-Thiazolylmethyl ((alphaS)-alpha-((1S,3S-1-hydroxy-3-((2S)-2-(3-((2-isopropyl-4-thiazolyl)methyl)-3-methylureido)-3-methylbutyramido)-4-phenylbutyl)phenethyl)carbamate
538, ABT
A-84538
ABBOTT-84538
ABT 538
ABT 84538
ABT-538
ABT538
AC-733
AC1L94GB
AKOS000280930
Abbott 84538
BIDD:GT0387
BIDD:PXR0023
Bio-0093
C07240
C37H48N6O5S2
CHEBI:45409
CHEMBL163
CID392622
CPD000466395
D00427
D019438
 
DB00503
DRG-0244
FT-0082824
HMS2051B08
HSDB 7160
LS-148860
MLS000759541
MLS001424063
MolPort-000-883-877
N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N~2~-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide
NCGC00159462-02
NSC693184
Norvir
Norvir (TM)
Norvir (TN)
Norvir Sec
RIT
RTV
Ritonavir
Ritonavir (JAN/USAN/INN)
Ritonavir [USAN]
Ritonavir is an inhibitor of HIV protease used to treat HIV infection and AIDS.
Ritonavirum
S1185_Selleck
SAM001246783
SMR000466395
STK634209
ZINC03944422
ritonavir
7
Oxaliplatinapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 1146061825-94-35310940, 9887054, 6857599, 9887054, 43805
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
 
Oxalatoplatinum
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
oxaliplatine
oxaliplatino
oxaliplatinum
8
Bevacizumabapproved, investigationalPhase 4, Phase 3, Phase 2, Phase 12020216974-75-3
Synonyms:
216974-75-3
Avastin
Avastin (TN)
Bevacizumab
Bevacizumab (genetical recombination)
 
Bevacizumab (genetical recombination) (JAN)
D06409
R-435
anti-VEGF monoclonal antibody
antiVEGF
bevacizumab
9
NevirapineapprovedPhase 4, Phase 3223129618-40-24463
Synonyms:
11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO[3,2-B:2',3'-E][1,4]DIAZEPIN-6-ONE
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[2,3-e:3',2'-b][1,4]diazepin-6-one & PRO 140 (Anti-CCR5 monoclonal antibody)
11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one
11-Cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-one
129618-40-2
1vrt
2hny
AC-643
AC1L1I81
BI RG 587
BI-RG-587
BI-RG-587 & CD4-IgG
BIDD:GT0326
BIRG 0587
BIRG 587
BIRG-0587
BIRG-587
BIRG587
Bio-0789
C07263
C15H14N4O
CHEBI:44659
CHEMBL57
CID4463
CPD000048458
Cahill May Roberts Brand of Nevirapine
D00435
D019829
DB00238
DB08311
 
HMS2051J09
HSDB 7164
I02-0310
LS-2289
MLS000084585
MLS000759409
MLS001055309
MLS001201730
MolPort-002-507-817
N11-Cyclopropyl-4-methyl-5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e]-[1,4]diazepin-6-one & CD4-immunoadhesin
NCGC00065890-02
NEV
NON-NUCLEOSIDE RT INHIBITOR NEVIRAPINE
NSC 641530
NSC641530
NVP
Nevirapine
Nevirapine & CD4-IgG
Nevirapine & PRO 140
Nevirapine (JAN/USP/INN)
Nevirapine [USAN:INN]
Promeco Brand of Nevirapine
S1742_Selleck
SAM001246551
SMR000048458
STK580320
UNII-99DK7FVK1H
Viramune
Viramune (TN)
Viramune(TM)
Viramune, BI-RG 587, Nevirapine
ZINC00004778
nevirapine
10
Lamivudineapproved, investigationalPhase 4, Phase 2, Phase 3621134678-17-460825
Synonyms:
(+/-) (Cis)-1-[2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(+/-)-3TC
(+/-)-BCH-189
(+/-)-SddC
(-)-(2'R,5'S)-1-[2'-Hydroxymethyl-5'-(1,3-oxathiolanyl)]cytosine
(-)-1-((2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
(-)-1-[(2R,5S)-2-(Hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-2'-Deoxy-3'-thiacytidine
(-)-BCH 189
(-)-BCH-189
(-)-SddC
(-)-beta-L-2',3'-Dideoxy-3'-thiacytidine
(-)NGPB-21
(2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
.beta.-L-(-)-2',3'-dideoxy-3'-thiacytidine & Sho-Saiko-To
134678-17-4
2',3' Dideoxy 3' thiacytidine
2',3'-Dideoxy-3'-thiacytidine
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (+/-) (Cis)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Galanthus Nivalis Agglutinin (GNA)
2(1H)-Pyrimidinone, 4-amino-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl], (-)(2R,5S) & Hippeastrum hybrid agglutinin( HHA)
3'-Thia-2',3'-dideoxycytidine
3TC
3TC & GNA
3TC & SST
3TC (AIDS INITIATIVE) (AIDS INITIATIVE)
3TC and NV-01
3TC, Zeffix, Heptovir, Epivir, Epivir-HBV, Lamivudine
4-Amino-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
480434-79-5
AC-1416
AC1L1TZZ
AC1Q6C34
BCH 189
BCH-189
BCH-790
BCH189
BIDD:GT0033
Bio-0652
C07065
C8H11N3O3S
CCRIS 9274
CHEBI:133986
CHEMBL141
CID60825
CPD000466319
D00353
D019259
 
DB00709
DRG-0126
DTHC
Epivir
Epivir (TN)
Epivir(TM)
Epivir-HBV
Epzicom
FT-0082667
GG-714
GR 109714X
GR-109714X
GR109714X
HHA & 3TC
HHA & Lamivudine
HMS2051D21
HSDB 7155
Hepitec
Heptivir
Heptodin
Heptovir
L0217
LMV
LS-2107
Lamivir
Lamivudin
Lamivudina
Lamivudine
Lamivudine & GNA
Lamivudine (JAN/USP/INN)
Lamivudine [USAN:BAN:INN]
Lamivudine [USAN:INN:BAN]
Lamivudine [Usan:Ban:Inn]
Lamivudine, (2S-cis)-Isomer
Lamivudinum
MLS000759424
MLS001424097
MolPort-002-507-347
NCGC00159341-03
NCGC00159341-04
NSC620753
S1706_Selleck
SAM001246582
SAM002589994
SMR000466319
STK801940
UNII-2T8Q726O95
ZINC00012346
Zeffix
Zefix
beta-L-2',3'-Dideoxy-3'-thiacytidine
beta-L-3'-Thia-2',3'-dideoxycytidine
lamivudine
11
Emtricitabineapproved, investigationalPhase 4, Phase 3457143491-57-060877
Synonyms:
(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
(-)-.beta.-L-FTC
(-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-2'-Deoxy-5-fluoro-3'-thiacytidine
(-)-FTC
(-)-beta-2',3'-Dideoxy-5-fluoro-3'-thiacytidine
(-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine
(-)-cis-4-amino-5-Fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one
(2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
(2R-cis)-4-amino-5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone
.beta.-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine
143491-54-7
143491-57-0
145213-48-5
2',3',5-FTC
2',3'-Dideoxy-5-fluoro-3'-thiacytidine
2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine
2'-Deoxy-5-fluoro-3'-thiacytidine
2-FTC
3'-Thia-2'.3'-dideoxy-5-fluorocytidine
4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one
4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
4-amino-5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one
4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one
5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine
5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine
524W91
AC1L1U3I
AC1Q4KUB
BW 1592
 
BW 524W91
BW-524W91
BW524W91
C122114
C12599
C8H10FN3O3S
CHEBI:31536
CHEMBL885
CID60877
Coviracil
Coviracil(TM)
D01199
DB00879
DRG-0208
Emtricitabin
Emtricitabina
Emtricitabine
Emtricitabine (JAN/USAN/INN)
Emtricitabinum
Emtriva
Emtriva (TN)
Emtriva(TM)
FT-0080009
HMS2089I05
HSDB 7337
LS-135838
LS-173184
NCGC00164564-01
RCV
Racivir
SBB066061
TL8000958
UNII-G70B4ETF4S
ZINC03629271
beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine
dOTFC
emtricitabine
12
LopinavirapprovedPhase 4, Phase 2, Phase 3344192725-17-092727
Synonyms:
(1S-(1R*(R*),3R*,4R*))-N-(4-(((2,6-Dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pyrimidineacetamide
(2S)-N-[(2S,4S,5S)-5-[[2-(2,6-dimethylphenoxy)acetyl]amino]-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxo-1,3-diazinan-1-yl)butanamide
(alphaS)-Tetrahydro-N-((alphaS)-alpha-((2S,3S)-2-hydroxy-4-phenyl-3-(2-(2,6-xylyloxy)acetamido)butyl)phenethyl)-alpha-isopropyl-2-oxo-1(2H)-pyrimidineacetamide
1(2H)-Pyrimidineacetamide, N-[(1S,3S,4S)-4-[[(2,6-dimethylphenoxy)acetyl]amino]-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl]tetrahydro-alpha-(1-methylethyl)-2-oxo-, (alphaS)- (9CI)
192725-17-0
1mui
2o4s
2q5k
2rkf
2rkg
A 157378
A 157378.0
A-157378-0
A-157378.0
AB1
ABT 157378
ABT 378
ABT-378
ABT-378, LOPINAVIR
AC1L3OPJ
AIDS032937
 
Aluviran
C12871
C37H48N4O5
CHEBI:40456
CHEMBL729
CID92727
D01425
DB01601
Koletra
LPV
LS-173766
Lopinavir
Lopinavir (JAN/USAN/INN)
Lopinavir [USAN:INN:BAN]
MolPort-003-848-410
N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide
N-{1-BENZYL-4-[2-(2,6-DIMETHYL-PHENOXY)-ACETYLAMINO]-3-HYDROXY-5-PHENYL-PENTYL}-3-METHYL-2-(2-OXO-TETRAHYDRO-PYRIMIDIN-1-YL)-BUTYRAMIDE
NCGC00164576-01
NCGC00164576-02
RS-346
S1380_Selleck
UNII-2494G1JF75
13
Tenofovirapproved, investigationalPhase 4, Phase 3759147127-20-6464205
Synonyms:
(R)-9-(2-Phosphonomethoxypropyl)adenine
(R)-9-(2-Phosphonylmethoxypropyl)adenine
(R)-9-(2-phosphonomethoxypropyl)adenine
(R)-PMPA
147127-20-6
206184-49-8
AC-760
AC1LA9BO
Anh. tenofovir
Anhydrous tenofovir
Apropovir
CHEBI:45809
CHEMBL483
CID464205
D,L-Tenofovir
DB00300
GNA & Tenofovir
GS 1275
GS 1278
GS1278
 
HHA & Tenofovir
KS-5021
MolPort-003-850-411
NCGC00167535-01
PMPA
PMPA-(R)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Galanthus nivalis agglutinin (GNA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- & Hippeastrum hybrid agglutinin( HHA)
Phosphonic acid, [[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]- (9CI)
Phosphonic acid, [[2-(6-amino-9H-purin-9
S1401_Selleck
TDF
TFV
Tenefovir
Tenofovir
Tenofovir (anh.)
Tenofovir disoproxil
Tenofovir disoproxil fumarate
UNII-99YXE507IL
Viread
Viread, Tenofovir
[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethylphosphonic acid
14
Capecitabineapproved, investigationalPhase 4, Phase 2, Phase 11342154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
15
Stavudineapproved, investigationalPhase 41723056-17-518283
Synonyms:
1-(2,3-Dideoxy-beta-D-glycero-2-pentenofuranosyl)thymine
1-(2,3-Dideoxy-beta-D-glycero-pent-2-enofuranosyl)thymine
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methylpyrimidine-2,4-dione
1-[5-(hydroxymethyl)-2,5-dihydro-2-furanyl]-5-methyl-2,4(1H,3H)-pyrimidinedione & Colony-stimulating factor 2
132425-31-1
2',3' Didehydro 3' deoxythymidine
2',3'-Anhydrothymidine
2',3'-DIDEHYDRO-3'-DEOXYTHYMIDINE (DDI)
2',3'-Didehydro-2',3'-dideoxythmidine
2',3'-Didehydro-3'-deoxythimidine
2',3'-Didehydro-3'-deoxythymidine
3'- Azido-3'-deoxythymidine & Granulocyte-macrophage colony-stimulating factor
3'-Deoxy-2',3'-didehydrothymidine
3'-Deoxy-2'-thymidinene
3056-17-5
AC-5263
AC1L2BQ9
AC1Q6BSH
BB_NC-1008
BIDD:GT0082
BMY 27857
BMY-27857
BMY27857
BRN 0618327
Bristol-Myers Brand of Stavudine
Bristol-Myers Squibb Brand of Stavudine
C07312
CHEBI:207119
CHEMBL991
CID18283
CPD000058350
CPD000673569
D 1413
D 4T
D 4T (nucleoside)
D00445
D018119
D1413_SIGMA
D3580
D4T & GM-CSF
D4TMBY-27857-3
DB00649
Dideoxydidehydrothymidine
EU-0100336
Estavudina
Estavudina [INN-Spanish]
FT-0082665
 
HMS2051O20
HSDB 7338
LS-1160
Lopac0_000336
MLS000028546
MLS000759504
MLS001055348
MLS001077292
MolPort-002-507-283
NCGC00023212-03
NCGC00023212-04
NCGC00023212-05
NCGC00023212-07
NCGC00023212-08
NCGC00023212-09
NCGC00023212-10
NSC 163661
NSC163661
SAM001246729
SAM002589948
SMR000058350
SMR000673569
STK801888
STV
Sanilvudine
Sanilvudine (JAN)
Stavudin
Stavudine
Stavudine (USAN/INN)
Stavudine [USAN:BAN:INN]
Stavudine [USAN:INN:BAN]
Stavudine [Usan:Ban:Inn]
Stavudine, Monosodium Salt
Stavudinum
Stavudinum [INN-Latin]
Thymine, 1-(2,3-dideoxy-beta-D-glycero-pent-2-enofuranosyl)- (7CI,8CI)
UNII-BO9LE4QFZF
ZINC00137884
Zent
Zerit
Zerit (TN)
Zerit XR
Zerit Xr
Zerit(TM)
Zerut XR
d4T
ddeThd
ddeTyd
sanilvudine
stavudine
16
Ethiodized oilapprovedPhase 4968008-53-5
Synonyms:
 
EOE 13
17
DoxilApproved June 1999Phase 4, Phase 3, Phase 2, Phase 1175131703
Synonyms:
Dox-SL
Doxil
 
Evacet
LipoDox
Pegylated Liposomal Doxorubicin Hydrochloride
liposomal doxorubicin
18
protease inhibitorsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 15471
Synonyms:
 
protease inhibitors
19Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 113086
20HIV Protease InhibitorsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 15470
21Antiviral AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 19967
22Antirheumatic AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 110956
23Topoisomerase InhibitorsPhase 4, Phase 3, Phase 2, Phase 15069
24Antineoplastic Agents, AlkylatingPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14603
25Antimetabolites, AntineoplasticPhase 4, Phase 2, Phase 3, Phase 17361
26Angiogenesis Modulating AgentsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 14185
27Angiogenesis InhibitorsPhase 4, Phase 3, Phase 1, Phase 2, Early Phase 14257
28Antibiotics, AntitubercularPhase 4, Phase 3, Phase 2, Phase 17180
29VaccinesPhase 4, Phase 1, Phase 26611
30Anti-Infective AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 122062
31AntimetabolitesPhase 4, Phase 2, Phase 3, Phase 112054
32Alkylating AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 14827
33Anti-Retroviral AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 13296
34Nucleic Acid Synthesis InhibitorsPhase 4, Phase 3, Phase 2, Phase 14962
35ImmunoglobulinsPhase 4, Phase 3, Phase 1, Phase 26394
36Anti-Bacterial AgentsPhase 4, Phase 3, Phase 2, Phase 1, Early Phase 111226
37AntibodiesPhase 4, Phase 3, Phase 1, Phase 26394
38Antibodies, MonoclonalPhase 4, Phase 3, Phase 1, Phase 24039
39Anti-HIV AgentsPhase 4, Phase 2, Phase 3, Phase 1, Early Phase 13162
40Antidepressive AgentsPhase 42736
41Antimanic AgentsPhase 4, Phase 1, Phase 2814
42Pharmaceutical SolutionsPhase 4, Phase 3, Phase 2, Phase 18192
43Tranquilizing AgentsPhase 4, Phase 2, Phase 14265
44Psychotropic DrugsPhase 4, Phase 2, Phase 16430
45Central Nervous System DepressantsPhase 4, Phase 2, Phase 3, Phase 113403
46Lithium carbonatePhase 4240554-13-2
47Cytochrome P-450 CYP2C9 InhibitorsPhase 4, Phase 3669
48Cytochrome P-450 CYP3A InducersPhase 4, Phase 3, Phase 2, Phase 11119
49Cytochrome P-450 CYP3A InhibitorsPhase 4, Phase 2, Phase 31715
50Reverse Transcriptase InhibitorsPhase 4, Phase 2, Phase 3, Phase 11913

Interventional clinical trials:

(show top 50)    (show all 1602)
idNameStatusNCT IDPhase
1EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in ChildrenUnknown statusNCT00339118Phase 4
2Optimizing Influenza Vaccination in Surgical Oncology PatientsUnknown statusNCT01698177Phase 4
3HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXTCompletedNCT00380770Phase 4
4Anti-Retrovirals for Kaposi's SarcomaCompletedNCT00444379Phase 4
5OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.CompletedNCT00577031Phase 4
6Physical Characteristics of Retrieved Massive AllograftsCompletedNCT00160758Phase 4
7HLA Sensitization Following Major Cortical Allograft Bone ProceduresCompletedNCT00160719Phase 4
8Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal CancerRecruitingNCT02301962Phase 4
9Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat OsteosarcomaRecruitingNCT01669369Phase 4
10Stereotactic Body Radiotherapy for Head and Neck TumorsActive, not recruitingNCT01344356Phase 4
11Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical ResectionNot yet recruitingNCT03144206Phase 4
12Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization.Not yet recruitingNCT02625389Phase 4
13The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine SarcomasUnknown statusNCT00162721Phase 3
14Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's SarcomaUnknown statusNCT00002516Phase 3
15Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue SarcomaUnknown statusNCT00334854Phase 3
16An Adequate Cost Effective Follow Up Protocol For Bone & Soft Tissue Sarcomas - A Prospective Randomized TrialUnknown statusNCT00384735Phase 3
17Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's SarcomaUnknown statusNCT00020566Phase 3
18A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's SarcomaUnknown statusNCT00002318Phase 3
19Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue SarcomaUnknown statusNCT00346164Phase 3
20Combination Chemotherapy in Treating Young Patients With Nonmetastatic RhabdomyosarcomaUnknown statusNCT00379457Phase 3
21TB-IRIS NSAID Cox-2 Inhibitor Prevention TrialUnknown statusNCT02060006Phase 3
22Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic CancerUnknown statusNCT01087268Phase 3
23Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity CancerUnknown statusNCT00954174Phase 3
24Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal TumorUnknown statusNCT00685828Phase 3
25Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal TumorUnknown statusNCT00103168Phase 3
26A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced OsteosarcomaUnknown statusNCT02099396Phase 2, Phase 3
27Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade OsteosarcomaUnknown statusNCT00691236Phase 2, Phase 3
28A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal SarcomaCompletedNCT00131898Phase 3
29Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue SarcomaCompletedNCT00142571Phase 3
30A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue SarcomaCompletedNCT01440088Phase 3
31Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal TumorCompletedNCT00006734Phase 3
32Doxorubicin in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedNCT00002985Phase 3
33Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior TherapyCompletedNCT00753688Phase 3
34Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00003212Phase 3
35An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)CompletedNCT00796120Phase 3
36Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00061984Phase 3
37Phase 3 Study to Treat Patients With Soft Tissue SarcomasCompletedNCT02049905Phase 3
38Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue SarcomaCompletedNCT00003052Phase 3
39Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or PelvisCompletedNCT00091351Phase 3
40Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue SarcomaCompletedNCT01168791Phase 3
41Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue SarcomaCompletedNCT01327885Phase 3
42A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's SarcomaCompletedNCT00002319Phase 3
43Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.CompletedNCT00002147Phase 3
44Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's SarcomaCompletedNCT00003350Phase 3
45A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in ZimbabweCompletedNCT00834457Phase 2, Phase 3
46Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)CompletedNCT00538239Phase 3
47Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS PatientsCompletedNCT00002445Phase 3
48A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue SarcomaCompletedNCT00001300Phase 3
49Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's SarcomaCompletedNCT00002105Phase 3
50Trial of Primary Prophylaxis With rhTPO Administered to Patients With High Risk Sarcoma Receiving Intensive ChemotherapyCompletedNCT00283582Phase 3

Search NIH Clinical Center for Sarcoma

Inferred drug relations via UMLS68/NDF-RT46:

Genetic Tests for Sarcoma

About this section

Genetic tests related to Sarcoma:

id Genetic test Affiliating Genes
1 Sarcoma27

Anatomical Context for Sarcoma

About this section

MalaCards organs/tissues related to Sarcoma:

36
Myeloid, Bone, Kidney, Liver, Breast, Lung, Endothelial

Publications for Sarcoma

About this section

Articles related to Sarcoma:

(show top 50)    (show all 8999)
idTitleAuthorsYear
1
Surveillance Imaging Patterns and Outcomes Following Radiation Therapy and Radical Resection for Localized Extremity and Trunk Soft Tissue Sarcoma. (28058559)
2017
2
Ewing sarcoma of the sternal manubrium: first report of a case in Australasia and review of the literature. (28419662)
2017
3
Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience. (28417551)
2017
4
Treatment of soft tissue sarcoma: a focus on earlier stages. (27918202)
2017
5
Alveolar soft part sarcoma with brain metastases. (28413551)
2017
6
Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor. (27696380)
2017
7
Biomarkers of Osteosarcoma, Chondrosarcoma, and Ewing Sarcoma. (28439237)
2017
8
Imaging investigations before referral to a sarcoma center delay the final diagnosis of musculoskeletal sarcoma. (28077058)
2017
9
Surgical management and outcome of spinal alveolar soft part sarcoma (ASPA): a case series of five patients and literature review. (28166791)
2017
10
CIC-DUX4 Induces Small Round Cell Sarcomas Distinct from Ewing Sarcoma. (28404587)
2017
11
DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1. (27894957)
2017
12
Laryngeal alveolar soft part sarcoma: A case report of a rare malignancy in an atypical location. (28131550)
2017
13
Acral pseudolymphomatous angiokeratoma of children with rainbow pattern: A mimicker of Kaposi sarcoma. (28087020)
2017
14
Long-term results of therapy with sunitinib in metastatic alveolar soft part sarcoma. (28291905)
2017
15
Is acquired arterial-venous fistula related to Kaposi sarcoma? (28214029)
2017
16
Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the Euro-EWING 99 trial. (28436593)
2017
17
Perilipin 1 is a highly specific marker for adipocytic differentiation in sarcomas with intermediate sensitivity. (27646609)
2017
18
Extra-skeletal Ewing sarcoma of the lumbosacral region in an adult pregnant patient: a case report. (28435928)
2017
19
Kaposi Sarcoma Inflammatory Cytokine Syndrome (KICS): A Rare but Potentially Treatable Condition. (28424322)
2017
20
Alveolar soft-part sarcoma of the mediastinum: A case report. (28321306)
2017
21
Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases. (28429277)
2017
22
RNA Sequencing Reveals that Kaposi Sarcoma-Associated Herpesvirus Infection Mimics Hypoxia Gene Expression Signature. (28046107)
2017
23
Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines. (28477025)
2017
24
Recombinant parvoviruses armed to deliver CXCL4L1 and CXCL10 are impaired in their antiangiogenic and antitumoral effects in a Kaposi sarcoma tumor model due to the chemokines' interference with the virus cycle. (28042949)
2017
25
Curcumin and Viscum album Extract Decrease Proliferation and Cell Viability of Soft-Tissue Sarcoma Cells: An In Vitro Analysis of Eight Cell Lines Using Real-Time Monitoring and Colorimetric Assays. (28045549)
2017
26
Kaposi sarcoma, oral malformations, mitral dysplasia, and scoliosis associated with 7q34-q36.3 heterozygous terminal deletion. (28488400)
2017
27
Dramatic Reduction in Tumor Size During 5 Months of Pazopanib Therapy in Combination With Ifosfamide, Carboplatin, and Etoposide in an Early Infant With Progressive Soft Tissue Sarcoma. (28067691)
2017
28
Bone adaptation of a biologically reconstructed femur after Ewing sarcoma: Long-term morphological and densitometric evolution. (28447127)
2017
29
Hepatic Kaposi sarcoma: A case report and review of the literature. (28217255)
2017
30
The importance of treating by histological subtype in advanced soft tissue sarcoma. (27918201)
2017
31
Kaposi Sarcoma in a patient treated with Ruxolitinib. (28419187)
2017
32
Antia89proliferative activity of epigallocatechina893a89gallate and silibinin on soft tissue sarcoma cells. (27909727)
2017
33
Inadvertently boarding a pirate ship: disease progression in a paediatric patient with relapsed metastatic Ewing sarcoma receiving treatment at a centre for alternative therapy in Mexico. (28062429)
2017
34
Correction: Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma. (28085948)
2017
35
Kaposi Sarcoma and Lung Transplant: Two Case Reports. (28501344)
2017
36
Kaposi Sarcoma Herpesvirus (KSHV) Latency-Associated Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-NBS1) repair complex to modulate an innate immune signaling pathway and viral latency. (28430817)
2017
37
Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model of Ewing Sarcoma. (27923328)
2017
38
Primary Bone Anaplastic Large Cell Lymphoma Masquerading as Ewing Sarcoma: Diagnosis by Anchored Multiplex PCR. (28452858)
2017
39
Associations of CD4+ T-cell count, HIV-1 RNA viral load, and antiretroviral therapy with Kaposi sarcoma risk among HIV-infected persons in the United States and Canada. (28394855)
2017
40
Primary Ewing sarcoma of the kidney: a case report and treatment review. (28509141)
2017
41
Quality of Survivorship in a Rare Disease: Clinicofunctional Outcome and Physical Activity in an Observational Cohort Study of 618 Long-Term Survivors of Ewing Sarcoma. (28355116)
2017
42
Ewing Sarcoma and Atypical Teratoid Rhabdoid Tumor. (28382842)
2017
43
Successful Treatment of Classic Kaposi Sarcoma With Long-Pulse Neodymium-Doped Yttrium Aluminum Garnet Laser: A Preliminary Study. (28157730)
2017
44
miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma. (27900663)
2017
45
Pulmonary Kaposi Sarcoma with Osseous Metastases in an Human Immunodeficiency Virus (HIV) Patient: A Remarkable Response to Highly Active Antiretroviral Therapy. (28216610)
2017
46
The Significant Effects of Pazopanib on Multiple Pulmonary Metastatic Lesions of Alveolar Soft Part Sarcoma: A Case Report. (28060129)
2017
47
Evolution in soft tissue sarcoma. (27918200)
2017
48
Classic Kaposi sarcoma in an HIV-negative Han Chinese man: a case report. (28329475)
2017
49
MDM2 gene polymorphisms and risk of classic Kaposi's sarcoma among Iranian patients. (28083704)
2017
50
Cost-Effectiveness Analysis of Preoperative Versus Postoperative Radiation Therapy in Extremity Soft Tissue Sarcoma. (28068242)
2017

Variations for Sarcoma

About this section

Clinvar genetic disease variations for Sarcoma:

5
id Gene Variation Type Significance SNP ID Assembly Location
1TP53NM_ 000546.5(TP53): c.743G> A (p.Arg248Gln)SNVPathogenic/ Likely pathogenicrs11540652GRCh37Chr 17, 7577538: 7577538
2PIK3CANM_ 006218.3(PIK3CA): c.1633G> A (p.Glu545Lys)SNVPathogenic/ Likely pathogenicrs104886003GRCh37Chr 3, 178936091: 178936091

Expression for genes affiliated with Sarcoma

About this section
Search GEO for disease gene expression data for Sarcoma.

Pathways for genes affiliated with Sarcoma

About this section

Pathways related to Sarcoma according to GeneCards Suite gene sharing:

(show top 50)    (show all 63)
idSuper pathwaysScoreTop Affiliating Genes
110.2HRAS, SRC
210.2CRK, JUN
3
Show member pathways
10.1BRAF, FES, SRC
4
Show member pathways
10.1BRAF, HRAS, SRC
5
Show member pathways
10.1BRAF, HRAS, SRC
610.1LYN, SRC, YES1
710.1LYN, SRC, YES1
810.1LYN, SRC, YES1
910.1LYN, SRC, YES1
10
Show member pathways
10.1LYN, SRC, YES1
1110.1LYN, SRC, YES1
1210.1LYN, SRC, YES1
1310.1LYN, SRC, YES1
1410.1BRAF, HRAS, LYN
1510.1BRAF, JUN, SRC
1610.1HRAS, JUN, SRC
1710.1HRAS, JUN, SRC
1810.1HRAS, JUN, SRC
1910.1CRK, LYN, YES1
2010.0CRK, HRAS, JUN
2110.0KIT, LYN, SRC, YES1
2210.0FES, HRAS, SRC, YES1
23
Show member pathways
10.0FES, HRAS, SRC, YES1
24
Show member pathways
10.0FES, HRAS, LYN, SRC
25
Show member pathways
10.0HRAS, LYN, SRC, YES1
26
Show member pathways
10.0HRAS, LYN, SRC, YES1
2710.0HRAS, LYN, SRC, YES1
28
Show member pathways
10.0BRAF, HRAS, JUN, KIT
2910.0BRAF, HRAS, JUN, SRC
30
Show member pathways
10.0BRAF, HRAS, JUN, SRC
31
Show member pathways
10.0BRAF, HRAS, JUN, SRC
3210.0BRAF, HRAS, JUN, SRC
33
Show member pathways
10.0CRK, LYN, SRC, YES1
3410.0CRK, LYN, SRC, YES1
3510.0CRK, LYN, SRC, YES1
36
Show member pathways
10.0CRK, LYN, SRC, YES1
3710.0HRAS, JUN, LYN, SRC
389.9CRK, HRAS, JUN, SRC
399.9CRK, HRAS, JUN, SRC
40
Show member pathways
9.9BRAF, CRK, HRAS, JUN
41
Show member pathways
9.9BRAF, CRK, HRAS, KIT, SRC
42
Show member pathways
9.9BRAF, HRAS, JUN, KIT, SRC
439.8BRAF, CRK, HRAS, JUN, KIT
44
Show member pathways
9.8BRAF, CRK, HRAS, JUN, SRC
45
Show member pathways
9.8BRAF, CRK, HRAS, JUN, SRC
46
Show member pathways
9.8BRAF, CRK, HRAS, JUN, SRC
479.8BRAF, CRK, HRAS, JUN, SRC
489.8BRAF, CRK, JUN, SRC, YES1
499.8CRK, HRAS, JUN, LYN, SRC
50
Show member pathways
9.8BRAF, CRK, HRAS, JUN, LYN

GO Terms for genes affiliated with Sarcoma

About this section

Cellular components related to Sarcoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1extrinsic component of cytoplasmic side of plasma membraneGO:003123410.8FES, LYN, SRC, YES1
2nucleusGO:00056348.3ASPSCR1, BRAF, CRK, EWSR1, FLI1, FUS

Biological processes related to Sarcoma according to GeneCards Suite gene sharing:

(show all 27)
idNameGO IDScoreTop Affiliating Genes
1myeloid progenitor cell differentiationGO:000231811.0BRAF, KIT
2positive regulation of actin cytoskeleton reorganizationGO:200025111.0FES, HRAS
3epidermal growth factor receptor signaling pathwayGO:000717310.9FES, HRAS, SRC
4cellular response to transforming growth factor beta stimulusGO:007156010.9CRK, SRC, YES1
5positive regulation of MAP kinase activityGO:004340610.9HRAS, KIT, SRC
6positive regulation of phosphatidylinositol 3-kinase activityGO:004355210.8KIT, LYN, SRC
7cellular response to calcium ionGO:007127710.8BRAF, FUS, JUN
8positive regulation of peptidyl-tyrosine phosphorylationGO:005073110.8LYN, SRC, YES1
9activation of MAPKK activityGO:000018610.8BRAF, CRK, MOS
10regulation of vascular permeabilityGO:004311410.8SRC, YES1
11positive regulation of MAPK cascadeGO:004341010.8HRAS, KIT, MOS
12regulation of mast cell degranulationGO:004330410.8FES, LYN
13leukocyte migrationGO:005090010.7HRAS, LYN, SRC, YES1
14peptidyl-tyrosine autophosphorylationGO:003808310.7FES, LYN, SRC, YES1
15Fc-gamma receptor signaling pathway involved in phagocytosisGO:003809610.7CRK, LYN, SRC, YES1
16MAPK cascadeGO:000016510.7BRAF, HRAS, KIT, MOS
17positive regulation of ERK1 and ERK2 cascadeGO:007037410.7BRAF, HRAS, JUN, SRC
18negative regulation of nucleic acid-templated transcriptionGO:190350710.6SSX1, SSX2, SSX3, SSX5
19peptidyl-tyrosine phosphorylationGO:001810810.6FES, KIT, LYN, SRC, YES1
20response to hydrogen peroxideGO:004254210.6CRK, JUN, SRC
21ephrin receptor signaling pathwayGO:004801310.4CRK, HRAS, LYN, SRC, SS18, YES1
22intracellular signal transductionGO:003555610.4BRAF, KIT, LYN, MOS, SRC, SS18
23protein autophosphorylationGO:004677710.4FES, KIT, LYN, MOS, SRC, YES1
24phosphorylationGO:001631010.3BRAF, FES, KIT, LYN, MOS, SRC
25regulation of cell proliferationGO:004212710.3BRAF, FES, JUN, KIT, SRC, YES1
26protein phosphorylationGO:000646810.2BRAF, FES, KIT, LYN, MOS, SRC
27T cell costimulationGO:003129510.1LYN, SRC, YES1

Molecular functions related to Sarcoma according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1signal transducer, downstream of receptor, with protein tyrosine kinase activityGO:000471610.8KIT, LYN
2non-membrane spanning protein tyrosine kinase activityGO:000471510.8FES, LYN, SRC, YES1
3enzyme bindingGO:001989910.6CRK, JUN, LYN, SRC, YES1
4protein tyrosine kinase activityGO:000471310.5FES, KIT, LYN, SRC, YES1
5nucleic acid bindingGO:000367610.5EWSR1, FUS, SSX1, SSX2, SSX3, SSX5
6kinase activityGO:001630110.4BRAF, FES, KIT, LYN, MOS, SRC
7protein kinase activityGO:000467210.2BRAF, FES, KIT, LYN, MOS, SRC
8transcription corepressor activityGO:00037149.9SSX1, SSX2, SSX3, SSX5
9protein bindingGO:00055158.5ASPSCR1, BRAF, CRK, EWSR1, FES, FLI1

Sources for Sarcoma

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet